December 10, 2018

The Centers for Disease Control and Prevention (CDC) has learned of an interruption in the supply of cycloserine, which is likely to last for at least the next several weeks. Until the supply of cycloserine is restored, it is recommended that patients should not be started on regimens that include cycloserine in order to reserve existing drug for patients who are already receiving it. For patients currently receiving cycloserine and for whom additional drug is completely unavailable, physicians will need to determine if another second-line drug should be substituted for the duration of the supply interruption. FDA will publish information on the status of this interruption, and where to obtain cycloserine once it becomes available on its website.

Physicians or programs who are unsure of what medication to substitute in the absence of cycloserine may contact CDC’s Division of Tuberculosis Elimination Centers of Excellence for Training, Education, and Medical Consultation (TB COE) for free medical consultation. 

• Southeastern National TB Center (SNTC) in Gainesville, Florida: 800-482-4636
• Curry International TB Center (CITC) in Oakland, California: 877-390-6682
• Global TB Institute (GTBI) in Newark, New Jersey: 800-482-3627
• Heartland National TB Center (HNTC) in San Antonio, Texas: 800-839-5864